PPARG and cancer: the VM_Score was also associated with low sensitivity to antiangiogenic and targeted therapies that target the FGFR3, β-catenin, and PPAR-γ pathways but are associated with high sensitivity to cancer immunotherapy, neoadjuvant chemotherapy, and radiotherapy.